Xeljanz ER Is Driving Growth for Pfizer This Year
Xeljanz ER growth trends
On February 24, 2016, the FDA approved Xeljanz XR, an extended-release form of the previously approved Xeljanz, as therapy for moderate-to-severe rheumatoid arthritis (or RA) in patients who did not respond properly or who could not tolerate methotrexate (or MTX) treatment. Unlike Xeljanz, which must be taken twice per day, Xeljanz ER is taken only once per day.
The reduced dosing frequency is expected to improve patient compliance rates, boosting the drug’s sales in 2016. To learn more about Xeljanz, please read Will Sales of Xeljanz Offset Falling Sales of Enbrel?
Interested in USMV? Don't miss the next report.
Receive e-mail alerts for new research on USMV
Wall Street analysts estimate that Xeljanz’s sales in 2016 will reach approximately $874 million, which would be a year-over-year (or YoY) decline of about 67.1%. In 2015, Xeljanz accounted for approximately 1.1% of Pfizer’s total revenues.
By the end of 2Q16, Xeljanz was prescribed to more than 50,000 patients around the world. Xeljanz has enabled Pfizer (PFE) to compete effectively with other RA players such as AbbVie (ABBV), Johnson & Johnson (JNJ), and Celgene (CELG).
If Xeljanz is able to surpass these revenues targets, it may boost Pfizer’s share price, as well as that of the iShares Edge MSCI Min Vol USA ETF (USMV). Pfizer makes up ~1.1% of USMV’s total portfolio holdings.
On July 28, 2016, Pfizer announced positive results from the Phase 3 trial testing efficacy of Xeljanz as therapy for patients suffering with moderate to severely active ulcerative colitis (or UC). Pfizer expects to submit application seeking the FDA’s approval for Xeljanz for UC in the first half of 2017. Additionally, Pfizer is exploring the use of Xeljanz as therapy for psoriatic arthritis.
In the next article, we’ll explore Pfizer’s strategy for its oncology portfolio in 2016.